RFL Insider Trading

Insider Ownership Percentage: 10.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Rafael Insider Trading History Chart

This chart shows the insider buying and selling history at Rafael by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$4M-$2M$0$2M$4MTotal Insider BuyingTotal Insider Selling

Rafael Share Price & Price History

Current Price: $1.67
Price Change: Price Increase of +0.07 (4.38%)
As of 04/17/2025 04:58 PM ET

This chart shows the closing price history over time for RFL up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$1.67Closing price on 04/18/25:

Rafael Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Rafael (NYSE:RFL)

11.30% of Rafael stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at RFL by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$23kbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$500k$0$500kTotal InflowsTotal Outflows
Rafael logo
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
Read More on Rafael

Today's Range

Now: $1.67
Low: $1.57
High: $1.70

50 Day Range

MA: $1.88
Low: $1.61
High: $2.11

52 Week Range

Now: $1.67
Low: $1.29
High: $2.50

Volume

42,587 shs

Average Volume

31,763 shs

Market Capitalization

$41.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99

Who are the major institutional investors of Rafael?

Rafael's top institutional investors include:
  1. Wealth Enhancement Advisory Services LLC — 0.05%
Learn More about top institutional investors of Rafael stock.

Which major investors are buying Rafael stock?

During the last quarter, RFL stock was purchased by institutional investors including:
  1. Wealth Enhancement Advisory Services LLC